{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T14:37:40Z","timestamp":1788964660181,"version":"build-2803163510"},"reference-count":32,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Technol Cancer Res Treat"],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Small cell lung cancer is sensitive to chemotherapy and radiotherapy, but local recurrence and distant metastasis occur shortly after treatment. This study aimed to evaluate the real-world value of anlotinib as a maintenance therapy in patients with extensive-stage small cell lung cancer (ES-SCLC) after first-line chemotherapy and consolidative thoracic radiotherapy (CTRT).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods<\/jats:title>\n                    <jats:p>A total of 150 patients with ES-SCLC treated with first-line chemotherapy and CTRT from April 2017 to December 2021 were retrospectively analyzed. After the completion of chemoradiotherapy, patients received anlotinib according to their desire. The primary endpoints were progression-free survival (PFS) and overall survival (OS) after the first diagnosis, and the secondary endpoints were prognostic factors and safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The ORR and DCR of patients with ES-SCLC were 50.0% and 80.3%, respectively, in the anlotinib group and 42.9% and 69.0% in the no-maintenance therapy group. The 3-year OS rates were 27.6% and 12.6% in the anlotinib and observation groups (HR\u2009=\u20092.52, P\u2009=\u20090.003), and the median OS times were 23.8 months and 15.3 months. The 3-year PFS rates were 18.2% and 8.8% in the anlotinib and observation groups (HR\u2009=\u20091.76, P\u2009=\u20090.034) with median PFS times of 11.5 months and 8.8 months. After stratification on the basis of clinical response, patients who achieved CR plus PR after chemoradiotherapy had a longer median OS in the anlotinib and observation groups (34.0 months vs 24.8 months, HR\u2009=\u20092.40, P\u2009=\u20090.009). There were higher incidence rates of hand\u2013foot syndrome (27.3% vs 10.5%, P\u2009=\u20090.001), gingival bleeding\/hemoptysis (18.5% vs 4.8%, P\u2009=\u20090.015) and rash (33.3% vs 4.8%, P\u2009&lt;\u20090.001) in the anlotinib group than in the observation group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Maintenance therapy with anlotinib improved the survival of patients with ES-SCLC after first-line chemotherapy and CTRT. Owing to the small sample size of the real-world trial, the reliability of our study needs to be confirmed in more studies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/15330338251317571","type":"journal-article","created":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T08:55:51Z","timestamp":1738313751000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":5,"title":["Anlotinib as Maintenance Therapy After First-Line Chemotherapy Combined with Consolidation Radiation for Extensive-Stage Small Cell Lung Cancer"],"prefix":"10.1177","volume":"24","author":[{"given":"Jinbo","family":"Ma","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Yantai Yuhuangding Hospital, Qingdao University, Yantai, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Yantai Yuhuangding Hospital, Qingdao University, Yantai, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Yantai Yuhuangding Hospital, Qingdao University, Yantai, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanliang","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Yantai Yuhuangding Hospital, Qingdao University, Yantai, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rukun","family":"Zang","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Yantai Yuhuangding Hospital, Qingdao University, Yantai, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolong","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Yantai Yuhuangding Hospital, Qingdao University, Yantai, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-1903-4794","authenticated-orcid":false,"given":"Jie","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Yantai Affiliated Hospital, Yantai Yuhuangding Hospital, Qingdao University, Yantai, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,1,31]]},"reference":[{"key":"bibr1-15330338251317571","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21492"},{"key":"bibr2-15330338251317571","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Small cell lung cancer version 3.2022 [Internet]. 2022. Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/nscl.pdf."},{"key":"bibr3-15330338251317571","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1809064"},{"key":"bibr4-15330338251317571","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30539-8"},{"key":"bibr5-15330338251317571","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-021-01131-w"},{"key":"bibr6-15330338251317571","doi-asserted-by":"publisher","DOI":"10.21037\/atm-22-12"},{"key":"bibr7-15330338251317571","doi-asserted-by":"publisher","DOI":"10.1586\/14737140.2015.1052410"},{"key":"bibr8-15330338251317571","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0154293"},{"key":"bibr9-15330338251317571","doi-asserted-by":"publisher","DOI":"10.1042\/BSR20182464"},{"key":"bibr10-15330338251317571","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01308"},{"issue":"1","key":"bibr11-15330338251317571","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-017-0548-2","volume":"11","author":"Shen G","year":"2018","journal-title":"J Hematol Oncol"},{"key":"bibr12-15330338251317571","doi-asserted-by":"publisher","DOI":"10.1177\/03008916221082704"},{"issue":"8","key":"bibr13-15330338251317571","first-page":"3679","volume":"13","author":"Kong F","year":"2023","journal-title":"Am J Cancer Res"},{"key":"bibr14-15330338251317571","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-147-8-200710160-00010"},{"key":"bibr15-15330338251317571","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.3941"},{"key":"bibr16-15330338251317571","doi-asserted-by":"publisher","DOI":"10.1177\/11795549211067184"},{"key":"bibr17-15330338251317571","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-021-01356-3"},{"key":"bibr18-15330338251317571","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-21-632"},{"key":"bibr19-15330338251317571","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2022.09.003"},{"key":"bibr20-15330338251317571","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-022-01279-7"},{"key":"bibr21-15330338251317571","first-page":"1","volume":"12","author":"Yuan J","year":"2022","journal-title":"Front Oncol"},{"key":"bibr22-15330338251317571","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S364125"},{"issue":"2021","key":"bibr23-15330338251317571","first-page":"1","volume":"10","author":"Petrelli F","year":"2022","journal-title":"F1000Res."},{"key":"bibr24-15330338251317571","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0214599"},{"issue":"2022","key":"bibr25-15330338251317571","first-page":"123","volume":"38","author":"Christ SM","year":"2023","journal-title":"Clin Transl Radiat Oncol"},{"key":"bibr26-15330338251317571","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15020434"},{"key":"bibr27-15330338251317571","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-20-305"},{"key":"bibr28-15330338251317571","doi-asserted-by":"publisher","DOI":"10.3747\/co.26.4481"},{"key":"bibr29-15330338251317571","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S174801"},{"key":"bibr30-15330338251317571","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-021-03858-2"},{"key":"bibr31-15330338251317571","doi-asserted-by":"publisher","DOI":"10.2147\/IJGM.S337316"},{"key":"bibr32-15330338251317571","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.5360"}],"container-title":["Technology in Cancer Research &amp; Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/15330338251317571","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/15330338251317571","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/15330338251317571","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T06:16:07Z","timestamp":1777702567000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/15330338251317571"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":32,"alternative-id":["10.1177\/15330338251317571"],"URL":"https:\/\/doi.org\/10.1177\/15330338251317571","relation":{"has-review":[{"id-type":"doi","id":"10.1177\/15330338251317571\/v3\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/15330338251317571\/v1\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/15330338251317571\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/15330338251317571\/v2\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/15330338251317571\/v2\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/15330338251317571\/v3\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/15330338251317571\/v2\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/15330338251317571\/v1\/review3","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/15330338251317571\/v1\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/15330338251317571\/v2\/response1","asserted-by":"object"}]},"ISSN":["1533-0346","1533-0338"],"issn-type":[{"value":"1533-0346","type":"print"},{"value":"1533-0338","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1]]},"article-number":"15330338251317571"}}